22
Disclosures
Jan 21, 2026 — Apr 13, 2026
Date Range
GROWTH
Market Segment
Pharmaceutical
Sector

Disclosures

DateTypeHeadlinePDF
Apr 13 Other Kubota Pharmaceutical Holdings Kubota Pharma Launches Monthly Subscription Service for Kubota Glass® PDF
Apr 7 Other Kubota Pharmaceutical Holdings Kubota Vision Begins GMP-Compliant API Production for Stargardt Disease Treatment Candidate Emicstator PDF
Mar 27 Earnings Kubota Pharmaceutical Holdings Kubota Pharmaceutical Reports Material Weakness in Financial Reporting Internal Controls PDF
Mar 27 Other Kubota Pharmaceutical Holdings Kubota Pharma Targets $1 Billion in European Starry Night Disease Drug Market PDF
Mar 25 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Ends Agreement With Sakata Pharma Over 'Kubota Glass' PDF
Mar 23 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Amends Audit Committee Changes Notice PDF
Mar 18 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Holds Board Meeting to Nominate Directors for Upcoming Shareholders' Meeting PDF
Mar 18 Equity Issuance Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Sets Shareholders Meeting for April 24 PDF
Mar 18 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical to Cut Capital Amid Financial Strategy Adjustments PDF
Mar 18 M&A Kubota Pharmaceutical Holdings: Issues 50,000 Stock Options PDF
Mar 18 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Changes Auditor Ahead of Annual Meeting PDF
Mar 18 Other Kubota Pharmaceutical Holdings: Kubota Pharmaceutical Introduces Restricted Share Award Plan for Directors PDF
Mar 18 Other Kubota Pharmaceutical Holdings: Kubota Pharma Signs Taiwan Sales Pact With FitGlasses PDF
Mar 18 M&A Kubota Pharmaceutical Holdings: Issues 1,750 Stock Options PDF
Feb 25 Admin Kubota Pharma Advances Talks With Laboratoires KÔL on Emicstat Salt PDF
Feb 18 Other Kubota CEO Withdraws Annual Salary Due to Sales Slump PDF
Feb 17 Equity Issuance Kubota Pharma Sees Revenue Boost From China Expansion; Targets Early Commercialization in Europe PDF
Feb 13 Earnings Kubota Pharmaceutical Holdings Co., Ltd. Reports FY25 Revenue of 21 million, Down 22% PDF
Feb 10 Forecast Kubota Pharmaceutical Lowers FY25 Forecast Due to Marketing Costs and R&D Expenses PDF
Jan 29 Other Kubota Pharmaceutical Meets Listing Standards for Fiscal Year End PDF
Jan 26 Admin Kubota Pharma Discusses Potential Deal with Laboratoires KÔL Over Emicstato Hydrochloride PDF
Jan 21 Other Kubota CEO Withdraws Compensation Amid Share Price Slump PDF

Disclosure Types

Other: 13 Earnings: 2 Equity Issuance: 2 M&A: 2 Admin: 2 Forecast: 1